BOSTON , Feb. 05, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the election of Robert Postma to its Board of Directors (the “Board”), effective immediately. Mr. Postma is the Founder of WaterMill Asset Management, a sizeable and
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON , Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of
BOSTON , Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the H.C.
– Advances Eden BioCell’s clinical program to validate Rapid Personalized Manufacturing (RPM) – – Clinical trial to study autologous CD19-specific CAR-T using RPM technology designed to reduce cost and simplify production for infusion the day after gene transfer – BOSTON , Dec.
Jaime Vieser and Holger Weis Elected to Board of Directors BOSTON , Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset
BOSTON , Dec. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that Satyavrat “Sath” Shukla, CFA, Chief Financial Officer, has informed the Company of his intention to step down from the role effective December 31, 2020 to pursue
Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by
Recommends A gainst E lecting WaterMill Nominee Jaime Vieser Ziopharm Continues to Recommend that Shareholders Support Company’s Strong Progress by Return ing the GREEN Consent Revocation Card BOSTON , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis BOSTON , Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology ,
ISS Acknowledges Ziopharm’s Outperformance of its Peer Group During Chairman Scott Tarriff’s Tenure Court Filings R aise Concerns About Professional Past of WaterMill Nominee Holger Weis Ziopharm Recommends Shareholders Return the GREEN Consent Revocation Card BOSTON , Nov.